Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Ubiquitin-Dependent Proteolysis

Highlights

  1. 1
    Nature communications · 2021
    ASAndrea SbonerBDBrian D. RobinsonCBChristopher BarbieriPZPengbo Zhou
    PMID: 34795264PMCID: PMC8602290DOISenior author37 citations
  2. 2
    The American journal of pathology · 2021
    NKNasser K AltorkiPZPengbo Zhou
    PMID: 34119472PMCID: PMC8420861DOISenior author3 citations
  3. 3
    Molecular & cellular oncology · 2022
    PZPengbo Zhou
    PMID: 35252555PMCID: PMC8890399DOISenior author6 citations

Publications

75 publications

Funding

20 grantsView NIH portfolio on RePORTER ↗

Active

3 grants
  • MPI
    Upstream and downstream targeting of the SPOP ubiquitin signaling pathway in prostate cancer
    National Cancer Institute · 2024–2029
    R01CA287724-02
  • MPI
    UBR5's Mechanisms of Action in Tumorigenesis and Immunoregulation
    National Cancer Institute · 2023–2028
    R01CA273716-03
  • Co-I
    Clinical and Translational Science Center - UL1
    National Center for Advancing Translational Sciences · 2017–2027· 2 renewals
    UL1TR002384-06
Completed grants (17)
  • Co-I
    Coordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate Cancer
    National Cancer Institute · 2018–2025
    R37CA215040-06
  • Sub-PI
    Small Molecule CUL4 Inhibitors as Dual Precision Oncology and Immuno-Oncology Drugs
    National Cancer Institute · 2021–2024 · via Culnexin Therapeutics LLC· 2 renewals
    R41CA265583-01S1
  • Sub-PI
    NExT Proposal S21-168 - CUL4 Project
    National Cancer Institute · 2021–2024 · via Leidos Biomedical Research
    75N91019D00024
  • PI
    G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate Tumorigenesis
    National Cancer Institute · 2018–2023
    R01CA221152-05
  • PI
    Harnessing the CRL4 Ubiquitin Ligase for Antagonizing Colorectal Carcinogenesis
    National Cancer Institute · 2017–2023
    R01CA213992-05
  • PI
    Addgene 703531
    Addgene, Inc. · 2022–2023
    Addgene 703531
  • Co-I
    Mechanisms of AHR Metabolic Toxicity
    National Institute of Environmental Health Sciences · 2017–2023
    R01ES027488-01
  • PI
    A microbial delivery system for anti-colorectal cancer ubiquibodies
    Cornell University · 2022–2022
    CU 222569-01
  • Sub-PI
    Topical Therapeutics for Skin Diseases associated with DNA Damage
    NYS Center for Advanced Technology, Institute of Biotechnology · 2018–2019 · via Cornell University - Ithaca
    C150124
  • Sub-PI
    Towards Understanding Prostate Cancer Heterogeneity
    National Cancer Institute · 2013–2019 · via Universitat Bern· 2 renewals
    R01CA125612-10
  • PI
    Ubiquitin Ligase as a Novel Diagnostic Marker and Therapeutic Target for Colorectal Cancer
    V Foundation Cancer Reseach · 2013–2018
    VF 13111522 EWOF
  • PI
    Tumorigenic Role of the CUL4A Ubiquitin Ligase
    National Cancer Institute · 2011–2018
    R01CA159925-05 EWOF
  • PI
    Regulation of Nucleotide Excision Repair by Proteolysis
    National Cancer Institute · 2009–2015
    R01CA098210-10 EW
  • PI
    Ubiquitin-Proteolytic Control of HOXA9 in Leukemogenesis
    National Cancer Institute · 2006–2012
    R01CA118085-05 EW
  • PI
    Development of High Throughput Assays to Identify Inhibitors of the CRL4 Ubiquitin Ligase
    National Institute of Neurological Disorders and Stroke · 2011–2012
    R21NS074087-01 EW
  • PI
    Protein Knockout Technology/Molecular Analysis of Cancer
    NCI · 2001–2006 · via NIH RePORTER
    R33CA092792-04
  • PI
    Protein Knockout Technology/Molecular Analysis of Cancer
    NCI · 2001–2002 · via NIH RePORTER
    R21CA092792-01

Clinical research

1 study

Active

1 study
  • PI
    Multi-Parameter IHC Profiling of EGFR-Mutated Lung Cancer: Enhancing Precision in Targeted and Immunotherapy
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)

Available technologies

3 technologiesView full WCM portfolio ↗

News mentions

2 mentionsView all WCM news ↗
  • 2022 Biomedical Business Plan Challenge Showcases Promising Startups
    June 3, 2022

    A promising venture that hopes to develop a new drug therapy for colorectal cancer won $50,000 in funding and recognition from experienced venture capitalists on May 26 at the annual Biomedical Business Plan Challenge.

  • COVID-19 Research Grants Support Weill Cornell Medicine Investigators
    September 11, 2020

    Weill Cornell Medicine has awarded eight grants of $100,000 each to faculty for a variety of research projects on COVID-19, funded by the institution’s Board of Overseers and additional donors. The grants will support studies aimed at understanding fundamental aspects of the disease, the body’s immune response and social determinants of health that affect COVID-19 outcomes.

Mentoring

3 menteesAll publications with mentees →

External relationships

Leadership Roles

CULGenesis INC

Ownership

CULGenesis INC · Culnexin Therapeutics LLC

Advisory/Scientific Board Member

Culnexin Therapeutics LLC

Proprietary Interest

Ship of Theseus LLC